Article Details

MB-106 Shows Early Promise in BTKi-Refractory Waldenström Macroglobulinemia/LPL

Retrieved on: 2024-06-21 16:08:14

Tags for this article:

Click the tags to see associated articles and topics

MB-106 Shows Early Promise in BTKi-Refractory Waldenström Macroglobulinemia/LPL. View article details on hiswai:

Excerpt

“Based on these data, the FDA has granted MB-106 orphan drug status and [regenerative medicine advanced therapy] designation for the treatment of ...

Article found on: www.onclive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up